Literature DB >> 23908492

Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome.

Christina C Chang1, Saleha Omarjee, Andrew Lim, Tim Spelman, Bernadett I Gosnell, William H Carr, Julian H Elliott, Mohamed-Yunus S Moosa, Thumbi Ndung'u, Martyn A French, Sharon R Lewin.   

Abstract

BACKGROUND: Human immunodeficiency virus-infected patients with treated cryptococcal meningitis who start combination antiretroviral therapy (cART) are at risk of further neurological deterioration, in part caused by paradoxical cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). We hypothesized that C-IRIS is associated with alterations of chemokine receptor expression on T cells and chemokine concentrations in cerebrospinal fluid (CSF) that enhance recruitment of T-helper 1 cells and/or myeloid cells to the central nervous system.
METHODS: In a prospective study of 128 human immunodeficiency virus-infected patients with cryptococcal meningitis who received antifungal therapy followed by cART, we examined the proportions of CD4(+) and CD8(+) T cells expressing CCR5 and/or CXCR3, in CSF and whole blood and the concentrations of CXCL10, CCL2, and CCL3 in stored CSF and plasma.
RESULTS: The proportion of CD4(+) and CD8(+) T cells expressing CXCR3(+)CCR5(+) and the concentrations of CXCL10, CCL2 and CCL3 were increased in CSF compared with blood at cART initiation (P < .0001). Patients with C-IRIS (n = 26), compared with those with no neurological deterioration (n = 63), had higher CSF ratios of CCL2/CXCL10 and CCL3/CXCL10 and higher proportions of CXCR3(+)CCR5(+)CD8(+)T cells in CSF compared with blood at cART initiation (P = .03, .0053, and .02, respectively).
CONCLUSION: CD8(+) T-cell and myeloid cell trafficking to the central nervous system may predispose patients to C-IRIS.

Entities:  

Keywords:  HIV; chemokines; cryptococcus; immune restoration disease

Mesh:

Substances:

Year:  2013        PMID: 23908492      PMCID: PMC3805241          DOI: 10.1093/infdis/jit388

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

Review 1.  CCL2: a potential prognostic marker and target of anti-inflammatory strategy in HIV/AIDS pathogenesis.

Authors:  Abdul W Ansari; Hans Heiken; Dirk Meyer-Olson; Reinhold E Schmidt
Journal:  Eur J Immunol       Date:  2011-11-10       Impact factor: 5.532

Review 2.  Chemokine receptors in the brain: their role in HIV infection and pathogenesis.

Authors:  Julio Martín-García; Dennis L Kolson; Francisco González-Scarano
Journal:  AIDS       Date:  2002-09-06       Impact factor: 4.177

Review 3.  The chemokine receptor CCR5 in the central nervous system.

Authors:  Silvia Sorce; Renier Myburgh; Karl-Heinz Krause
Journal:  Prog Neurobiol       Date:  2010-12-14       Impact factor: 11.685

4.  A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists.

Authors:  Nalin L Subasinghe; James Lanter; Thomas Markotan; Evan Opas; Sandra McKenney; Carl Crysler; Cuifen Hou; John O'Neill; Dana Johnson; Zhihua Sui
Journal:  Bioorg Med Chem Lett       Date:  2012-12-20       Impact factor: 2.823

5.  IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis.

Authors:  Asna A Siddiqui; Annemarie E Brouwer; Vannaporn Wuthiekanun; Shabbar Jaffar; Robin Shattock; Diane Irving; Joanna Sheldon; Wirongrong Chierakul; Sharon Peacock; Nicholas Day; Nicholas J White; Thomas S Harrison
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

Review 6.  Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.

Authors:  Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

7.  A novel C-C chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models.

Authors:  Masayuki Okamoto; Masahiro Fuchigami; Takeshi Suzuki; Nobuhide Watanabe
Journal:  Biol Pharm Bull       Date:  2012       Impact factor: 2.233

8.  Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-γ responses before antiretroviral therapy but not higher T-cell responses during therapy.

Authors:  Christina C Chang; Andrew Lim; Saleha Omarjee; Stuart M Levitz; Bernadett I Gosnell; Tim Spelman; Julian H Elliott; William H Carr; Mohamed-Yunus S Moosa; Thumbi Ndung'u; Sharon R Lewin; Martyn A French
Journal:  J Infect Dis       Date:  2013-06-12       Impact factor: 5.226

9.  Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection.

Authors:  O Lortholary; L Improvisi; N Rayhane; F Gray; C Fitting; J M Cavaillon; F Dromer
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

10.  A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection.

Authors:  Chung-Her Jenh; Mary Ann Cox; Long Cui; Eva-Pia Reich; Lee Sullivan; Shu-Cheng Chen; David Kinsley; Shiguang Qian; Seong Heon Kim; Stuart Rosenblum; Joseph Kozlowski; Jay S Fine; Paul J Zavodny; Daniel Lundell
Journal:  BMC Immunol       Date:  2012-01-10       Impact factor: 3.615

View more
  39 in total

1.  Immune reconstitution disorders in patients with HIV infection: from pathogenesis to prevention and treatment.

Authors:  C C Chang; V Sheikh; I Sereti; M A French
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

2.  Compartmentalization of innate immune responses in the central nervous system during cryptococcal meningitis/HIV coinfection.

Authors:  Vivek Naranbhai; Christina C Chang; Raveshni Durgiah; Saleha Omarjee; Andrew Lim; Mahomed-Yunus S Moosa; Julian H Elliot; Thumbi Ndung'u; Sharon R Lewin; Martyn A French; William H Carr
Journal:  AIDS       Date:  2014-03-13       Impact factor: 4.177

3.  Update on fungal diagnostics.

Authors:  Allen T Griffin; Kimberly E Hanson
Journal:  Curr Infect Dis Rep       Date:  2014-08       Impact factor: 3.725

Review 4.  Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy.

Authors:  Peter R Williamson; Joseph N Jarvis; Anil A Panackal; Matthew C Fisher; Síle F Molloy; Angela Loyse; Thomas S Harrison
Journal:  Nat Rev Neurol       Date:  2016-11-25       Impact factor: 42.937

Review 5.  New insights into immune reconstitution inflammatory syndrome of the central nervous system.

Authors:  Tory P Johnson; Avindra Nath
Journal:  Curr Opin HIV AIDS       Date:  2014-11       Impact factor: 4.283

Review 6.  Cryptococcosis.

Authors:  Eileen K Maziarz; John R Perfect
Journal:  Infect Dis Clin North Am       Date:  2016-03       Impact factor: 5.982

Review 7.  The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum.

Authors:  David B Meya; Yukari C Manabe; David R Boulware; Edward N Janoff
Journal:  Curr Opin Infect Dis       Date:  2016-02       Impact factor: 4.915

8.  Regulatory T Cell Induction and Retention in the Lungs Drives Suppression of Detrimental Type 2 Th Cells During Pulmonary Cryptococcal Infection.

Authors:  Darin L Wiesner; Kyle D Smith; Dmitri I Kotov; Judith N Nielsen; Paul R Bohjanen; Kirsten Nielsen
Journal:  J Immunol       Date:  2015-11-20       Impact factor: 5.422

Review 9.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

10.  Understanding mechanisms underlying the pathology of immune reconstitution inflammatory syndrome (IRIS) by using animal models.

Authors:  Nupur Aggarwal; William Barclay; Mari L Shinohara
Journal:  Curr Clin Microbiol Rep       Date:  2018-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.